全文获取类型
收费全文 | 305篇 |
免费 | 20篇 |
国内免费 | 1篇 |
专业分类
儿科学 | 4篇 |
妇产科学 | 1篇 |
基础医学 | 48篇 |
口腔科学 | 5篇 |
临床医学 | 29篇 |
内科学 | 44篇 |
皮肤病学 | 5篇 |
神经病学 | 23篇 |
特种医学 | 37篇 |
外科学 | 56篇 |
综合类 | 5篇 |
预防医学 | 9篇 |
眼科学 | 23篇 |
药学 | 24篇 |
中国医学 | 1篇 |
肿瘤学 | 12篇 |
出版年
2023年 | 3篇 |
2022年 | 2篇 |
2021年 | 10篇 |
2020年 | 4篇 |
2019年 | 9篇 |
2018年 | 12篇 |
2017年 | 9篇 |
2016年 | 8篇 |
2015年 | 11篇 |
2014年 | 7篇 |
2013年 | 11篇 |
2012年 | 25篇 |
2011年 | 20篇 |
2010年 | 15篇 |
2009年 | 3篇 |
2008年 | 22篇 |
2007年 | 7篇 |
2006年 | 15篇 |
2005年 | 7篇 |
2004年 | 7篇 |
2003年 | 8篇 |
2002年 | 9篇 |
2001年 | 10篇 |
2000年 | 3篇 |
1999年 | 9篇 |
1998年 | 3篇 |
1997年 | 2篇 |
1996年 | 3篇 |
1995年 | 2篇 |
1994年 | 2篇 |
1992年 | 4篇 |
1991年 | 2篇 |
1990年 | 5篇 |
1989年 | 3篇 |
1988年 | 3篇 |
1987年 | 4篇 |
1980年 | 4篇 |
1979年 | 3篇 |
1978年 | 4篇 |
1975年 | 3篇 |
1974年 | 4篇 |
1973年 | 3篇 |
1971年 | 2篇 |
1970年 | 1篇 |
1968年 | 4篇 |
1967年 | 1篇 |
1966年 | 4篇 |
1965年 | 2篇 |
1961年 | 3篇 |
1960年 | 2篇 |
排序方式: 共有326条查询结果,搜索用时 0 毫秒
41.
42.
43.
Ulrich Schneider Bernhard Schmidt-Rohlfing Karsten Gavenis Uwe Maus Ralf Mueller-Rath Stefan Andereya 《Knee surgery, sports traumatology, arthroscopy》2011,19(12):2145-2152
Purpose
The value of cell-free techniques in the treatment of cartilage defects remains under debate. In this study, cartilage repair of full-thickness chondral defects in the knees of Goettinger minipigs was assessed by treatment with a cell-free collagen type-I gel or a collagen type-I gel seeded with autologous chondrocytes. As a control, abrasion arthroplasty was included. 相似文献44.
45.
Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial 总被引:3,自引:0,他引:3
Ziegler D Ametov A Barinov A Dyck PJ Gurieva I Low PA Munzel U Yakhno N Raz I Novosadova M Maus J Samigullin R 《Diabetes care》2006,29(11):2365-2370
OBJECTIVE: The aim of this trial was to evaluate the effects of alpha-lipoic acid (ALA) on positive sensory symptoms and neuropathic deficits in diabetic patients with distal symmetric polyneuropathy (DSP). RESEARCH DESIGN AND METHODS: In this multicenter, randomized, double-blind, placebo-controlled trial, 181 diabetic patients in Russia and Israel received once-daily oral doses of 600 mg (n = 45) (ALA600), 1,200 mg (n = 47) (ALA1200), and 1,800 mg (ALA1800) of ALA (n = 46) or placebo (n = 43) for 5 weeks after a 1-week placebo run-in period. The primary outcome measure was the change from baseline of the Total Symptom Score (TSS), including stabbing pain, burning pain, paresthesia, and asleep numbness of the feet. Secondary end points included individual symptoms of TSS, Neuropathy Symptoms and Change (NSC) score, Neuropathy Impairment Score (NIS), and patients' global assessment of efficacy. RESULTS: Mean TSS did not differ significantly at baseline among the treatment groups and on average decreased by 4.9 points (51%) in ALA600, 4.5 (48%) in ALA1200, and 4.7 (52%) in ALA1800 compared with 2.9 points (32%) in the placebo group (all P < 0.05 vs. placebo). The corresponding response rates (>/=50% reduction in TSS) were 62, 50, 56, and 26%, respectively. Significant improvements favoring all three ALA groups were also noted for stabbing and burning pain, the NSC score, and the patients' global assessment of efficacy. The NIS was numerically reduced. Safety analysis showed a dose-dependent increase in nausea, vomiting, and vertigo. CONCLUSIONS: Oral treatment with ALA for 5 weeks improved neuropathic symptoms and deficits in patients with DSP. An oral dose of 600 mg once daily appears to provide the optimum risk-to-benefit ratio. 相似文献
46.
BMP-2 incorporated in a tricalcium phosphate bone substitute enhances bone remodeling in sheep 总被引:1,自引:0,他引:1
Maus U Andereya S Gravius S Ohnsorge JA Niedhart C Siebert CH 《Journal of biomaterials applications》2008,22(6):559-576
Bone morphogenetic protein-2 (BMP-2) is a well-known osteoinductive protein, which requires a carrier for local application. As an alternative to the previously described carriers, an in situ hardening, resorbable, and osteoconductive beta-tricalcium phosphate cement (TCP) is tested. Trepanation defects in the bovine distal femoral epiphysis are filled with a composite consisting of TCP and 200 microg rhBMP-2 per cm3 TCP, autologous bone graft, pure TCP, or left empty. A radiological follow-up is performed after 7 weeks and 3 months. The sheep are euthanized and bone samples are analyzed by microradiography, histology, and histomorphometry. Microradiography and histology show similar results for pure TCP and the composite. The defects are filled with trabecular bone and newly formed bone is in close contact with the remaining TCP-particles. The majority of the cement is resorbed, in the composite group the amount of remaining cement particles is reduced. Defects treated with autologous bone graft are filled completely, while untreated defects shows only a small amount of bone originating from the rim of the defect. Histomorphometry of the defects treated with pure TCP shows a significantly increased bone content in comparison to defects treated with the composite or autologous bone graft. Analysis of the remaining cement particles shows significantly less cement in the TCP/rhBMP-2 group in comparison to pure TCP. The sum of bone and cement content in the rhBMP-2 group shows amounts comparable to the calcified structures found following autologous bone grafting. The addition of rhBMP-2 to the TCP leads to faster remodeling of the defect comparable to autologous bone graft, while defects treated with pure TCP are not completely remodeled. 相似文献
47.
Caroline E. Fife Suzanne Davey Erik A. Maus Renie Guilliod Harvey N. Mayrovitz 《Supportive care in cancer》2012,20(12):3279-3286
Purpose
Pneumatic compression devices (PCDs) are used in the home setting as adjunctive treatment for lymphedema after acute treatment in a clinical setting. PCDs range in complexity from simple to technologically advanced. The objective of this prospective, randomized study was to determine whether an advanced PCD (APCD) provides better outcomes as measured by arm edema and tissue water reductions compared to a standard PCD (SPCD) in patients with arm lymphedema after breast cancer treatment.Methods
Subjects were randomized to an APCD (Flexitouch system, HCPCS E0652) or SPCD (Bio Compression 2004, HCPCS E0651) used for home treatment 1?h/day for 12?weeks. Pressure settings were 30?mmHg for the SPCD and upper extremity treatment program (UE01) with standard pressure for the APCD. Thirty-six subjects (18 per group) with unilateral upper extremity lymphedema with at least 5% arm edema volume at the time of enrollment, completed treatments over the 12-week period. Arm volumes were determined from arm girth measurements and suitable model calculations, and tissue water was determined based on measurements of the arm tissue dielectric constant (TDC).Results
The APCD-treated group experienced an average of 29% reduction in edema compared to a 16% increase in the SPCD group. Mean changes in TDC values were a 5.8% reduction for the APCD group and a 1.9% increase for the SPCD group.Conclusion
This study suggests that for the home maintenance phase of treatment of arm lymphedema secondary to breast cancer therapy, the adjuvant treatment with an APCD provides better outcomes than with a SPCD. 相似文献48.
Adrienn Volak Stanley G. LeRoy Jeya Shree Natasan David J. Park Pike See Cheah Andreas Maus Zachary Fitzpatrick Eloise Hudry Kelsey Pinkham Sheetal Gandhi Bradley T. Hyman Dakai Mu Dwijit GuhaSarkar Anat O. Stemmer-Rachamimov Miguel Sena-Esteves Christian E. Badr Casey A. Maguire 《Journal of neuro-oncology》2018,139(2):293-305
49.
Königs P Rinker B Maus L Nieger M Rheinheimer J Waldvogel SR 《Journal of natural products》2010,73(12):2064-2066
The chromone "altechromone A" was synthesized as a substructure in the course of natural product synthesis. Its architecture was verified by X-ray analysis, but spectroscopic data showed a strong deviation from the reported data. By comparison with the synthesized isomers the structure of altechromone A was revised. 相似文献
50.
S Kadam M Maus J Poddig S Schmidt R Rasmussen E Novosad J Plattner J McAlpine 《Cancer research》1992,52(17):4735-4740
Two new fused indoles were found to overcome multidrug resistance in P388/Adr cells in vitro. These agents potentiated the cytotoxicity of the antitumor drugs Adriamycin, vinblastine, and vincristine in multidrug-resistant cells with no effect on drug-sensitive parent P388 cells. They significantly increased the ATP-dependent accumulation of [3H]-vinblastine and inhibited efflux of the labeled drug from resistant cells. These compounds also inhibited photoaffinity labeling of P-glycoprotein by [3H]azidopine in P388/Adr cells and membranes isolated from these cells. In addition, the calcium antagonist activity of these compounds was very weak compared with that of verapamil. These data suggest that the compounds reported here may specifically overcome multidrug resistance without the serious hypotensive effects associated with calcium antagonists and that this activity may be independent of their ability to block calcium transport. 相似文献